Novelix Pharmaceuticals Peer Comparison

BSE: 536565

₹74.14

₹-3.36 (-4.34%)

As on 22-Sep-2026IST

Market cap

₹211 Cr

Revenue (TTM)

₹147 Cr

P/E Ratio

58.1

P/B Ratio

3.3

Div. Yield

0 %

Edit

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	211	21,126	20,208	17,656	18,275
Revenue (₹ Cr)	147	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	3.63	678.07	273.51	666.92	735.15
Net Margin (%)	2.47	28.10	16.19	20.60	26.88
RoE (%)	10.07	19.73	11.15	18.75	19.16
Price to Earnings	58.15	31.75	67.97	27.42	24.86
Price-To-Book	3.32	5.75	7.52	4.38	4.15

Income Statement (₹ Cr)

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	30.72	1,937.47	1,286.43	2,893.64	2,281.35
Total Income	30.73	2,033.90	1,322.88	2,912.00	2,453.60
Total Expenditure	30.57	1,290.54	980.18	1,876.44	1,541.03
EBITDA	0.15	646.93	306.25	1,017.20	740.32
Depreciation	0.04	65.96	112.99	315.46	60.79
EBIT	0.11	580.97	193.26	701.74	679.53
Interest	0.00	0.61	75.53	231.29	8.50
Other Income	0.02	96.43	36.45	18.36	172.25
Exceptional Items	--	--	-30.58	--	172.81
Profit before Tax	0.12	676.78	122.33	488.87	1,016.09
Provision for Tax	0.04	135.69	44.04	114.20	248.49
Profit after Tax	0.08	541.09	78.29	374.67	767.60

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	17.54	2,850.49	2,362.70	2,854.36	4,217.41
Minority Interest	--	35.90	1.04	417.40	--
Non-Current Liabilities	-0.04	13.24	259.78	2,100.97	54.89
Current Liabilities	9.67	305.99	674.19	1,492.79	569.51
Total Liabilities	27.21	3,207.85	3,310.68	6,865.52	4,911.11

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	0.23	1,071.67	2,313.20	5,531.13	1,328.96
Current Assets	26.93	2,133.95	984.51	1,334.39	3,512.85
Total Assets	27.21	3,207.85	3,310.68	6,865.52	4,911.11
Total Debt*	0.00	0.55	586.37	2,421.66	2.50
Net Current Assets	17.27	1,827.96	310.32	-158.40	2,943.34
Contingent Liabilities	--	0.64	76.22	51.96	363.79

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	-13.68	432.37	132.27	1,065.01	659.75
Cash Flow from Investing Activities	2.93	-334.73	-199.13	-79.97	-71.34
Cash from Financing Activities	11.32	-38.32	62.65	-881.32	-205.34
Net Cash Inflow / Outflow	0.56	59.32	-4.21	103.72	383.07

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	1.00	26.22	6.95	13.59	26.21
ROE (%)	0.68	21.72	3.75	13.81	19.65
ROA (%)	0.49	18.37	2.45	5.48	17.03
EBIT Margin (%)	0.53	38.37	26.64	35.79	40.00
Net Margin (%)	0.28	26.60	5.92	12.87	31.28
Cash Profit Margin (%)	0.40	31.33	14.87	23.21	34.70

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	627.27	14.37	11.71	44.02	4.02
EBIT Growth (%)	166.83	20.21	35.64	48.22	11.86
Net Profit Growth (%)	711.76	17.27	145.00	-5.65	39.23
EPS Growth (%)	558.14	17.25	118.00	-10.39	39.23
Book Value Growth (%)	138.48	23.77	30.63	10.19	17.30

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	313.43	28.38	41.41	54.83	23.86
Price / Book Value	1.51	5.52	2.74	6.78	4.34
Dividend Yield (%)	0.00	0.30	0.15	0.52	4.12
EV/EBITDA	159.27	19.78	20.55	20.75	17.01
Market Cap (₹ Cr)	26.48	15,219.80	6,484.12	19,292.77	18,318.10

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	0.00	0.00	0.25	0.85	0.00
Short term debt to equity ratio	--	0.00	0.13	0.14	0.00
Current Ratio	2.79	6.97	1.46	0.89	6.17
Quick Ratio	2.70	5.88	0.94	0.67	5.33
Interest Coverage	192.23	1,110.48	2.62	3.11	120.54

	Novelix Pharmaceuticals	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	59.04	32.65	34.26	15.85	8.46
Asset Turnover	1.78	0.66	0.40	0.43	0.53
Receivable days	107.83	110.70	118.15	54.06	29.10
Inventory Days	12.11	65.86	98.29	32.16	69.53
Payable days	57.42	105.88	128.16	140.91	76.77
Cash Conversion Cycle	62.52	70.68	88.28	-54.69	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.